News

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy, according to analysts. On June 7, Eli Lilly and Company (NYSE:LLY) announced top-line results for Foundayo (orforglipron), the only oral GLP-1 that can be taken without food or water restrictions. Clinical trial results showed that women with obesity and who were […]

Investing.com -- Elon Musk’s SpaceX on Thursday said that it has priced its initial public offering at $135 per share on Thursday, raising $75 billion in the largest IPO in U.S. history.

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very different stories about who ... Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

The $5.3 billion ambient AI startup is expanding from clinical notes into billing, drug trials, and real-time insurance claims.

Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

Rising use of weight-loss drugs keeps pressure on health benefit costs.

ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.

The AI boom has been built on a simple assumption: the companies with the best models will capture most of the value. That belief helped push valuations for leading AI developers into the hundreds of billions of dollars and turned model performance benchmarks into headline news. But markets have a habit of changing the rules. ... An AI Price War Is About to Break Out. You Won’t Believe Who Will Profit Most

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food’s addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, ... The GLP-1 stock nobody is pricing in isn’t a drugmaker

FDA approves an extended once-every-eight-weeks maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. The decision expands Eli Lilly's (NYSE:LLY) dermatology footprint beyond its obesity and diabetes drug franchises. Ebglyss already has broad coverage from national pharmacy benefit managers, and the new regimen provides added dosing flexibility for patients. For you as an investor, this FDA decision adds another dimension to Eli Lilly's...

I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one. They each do something I cannot replicate by being clever. Why the buy button stays active on NVIDIA NVIDIA (NASDAQ:NVDA) ... I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.

Eli Lilly and other defensive names gain favor as AI overspending fears spark a sharp rotation out of tech and semiconductor stocks.

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.

By Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

Pfizer (NYSE:PFE) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1. Yet the stock is up only 6.37% YTD this year. Can Pfizer shares double to $50 by 2031? What’s Holding Pfizer Back Pfizer is down 0.23% over the past month and essentially flat ... Prediction: Pfizer Stock Will Double on This Date

Eli Lilly’s latest analyst update comes with no changes to the existing price targets, keeping the current benchmarks in place for now. In the sections ahead, you will see how to track these price targets over time and follow the evolving analyst narrative around the stock. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Eli Lilly. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the...

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Stocks to Buy According to D. E. Shaw. On June 9, Jefferies raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330. It reiterated a Buy rating on the shares. The move followed the release of full data from […]

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy. On June 7, Eli Lilly’s oral GLP-1 medication, Foundayo (orforglipron), demonstrated significant efficacy in promoting weight loss for women across all stages of menopause. Results from post-hoc analyses of the ATTAIN-1 and ATTAIN-2 clinical trials, presented at the American Diabetes […]

FDA approval expands EBGLYSS maintenance dosing to once every eight weeks, offering fewer injections for patients with moderate-to-severe atopic dermatitis.

The milestone shows strong early demand as Novo competes with Lilly in oral weight-loss drugs.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and

Dow Jones AI giant Nvidia stock tumbled to a key support level during Tuesday's stock market sell-off. A decisive bounce would be bullish.

AI Stocks are getting hammered on renewed overspending fears. Is this the start of the end?